PD L1 News and Research

RSS

Dual treatment strategies lengthen lives of mice with skin cancer

By combining two treatment strategies, both aimed at boosting the immune system's killer T cells, Johns Hopkins researchers report they lengthened the lives of mice with skin cancer more than by using either strategy on its own.

21 Dec 2016

New Forsyth study provides new foundation for fighting Sjögren's syndrome

Sjögren's syndrome is the second most common autoimmune disease affecting four million Americans--yet treatments are limited due to a lack of knowledge about its causes.

14 Dec 2016

PD-1 protein could serve as biomarker for predicting survival of lung cancer patients

The biomarker PD-1, a protein, could potentially be used to predict survival or disease-free survival of lung cancer patients who have had the tumour surgically removed.

6 Dec 2016

Study suggests new approach to treat white blood cells of sepsis patients

New research findings published in the Journal of Leukocyte Biology, suggest that treating the white blood cells of sepsis patients with antibodies that block programmed cell death-1 (PD-1) and programmed cell death ligand (PD-L1) molecules may restore their function and ultimately their ability to eradicate deadly bacteria.

1 Dec 2016

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Pembrolizumab was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen.

22 Nov 2016

Researchers focus on optimal use of immune agents in frontline setting for NSCLC treatment

Immunotherapy continues to revolutionize the field of non-small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.

18 Nov 2016

Immunotherapy drug approved by FDA as first-line treatment for non-small cell lung cancer

Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).

25 Oct 2016

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

8 Oct 2016

Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.

7 Oct 2016

Research shows how new ovarian cancer treatment could help boost anti-tumor immunity

Few effective treatments have been approved to treat ovarian cancer, the deadliest of all cancers affecting the female reproductive system.

3 Oct 2016

Yale researchers compare efficacy of four PD-L1 assay tests

In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests.

23 Sep 2016

BET inhibitors could be powerful new therapeutic strategy for ovarian cancer

Few effective treatments have been approved to treat ovarian cancer, the deadliest of all cancers affecting the female reproductive system.

14 Sep 2016

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy.

19 Aug 2016

New clinical trial to examine safety of checkpoint inhibitor in pediatric cancer patients

In an innovative, first-in-pediatrics study, available only at Children's Hospital Los Angeles, researchers will be enrolling children between 1 and 18 years of age who have certain types of relapsed or treatment-resistant cancer.

18 Aug 2016

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery.

11 Aug 2016

PD-1-responsive T cells may offer clues to design more effective drugs for cancer

Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs.

3 Aug 2016

Roche announces FDA approval of new VENTANA PD-L1 assay

Roche today announced approval of the VENTANA PD-L1 (SP142) Assay by the US Food and Drug Administration as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with the FDA approved Roche immunotherapy TECENTRIQ™ (atezolizumab) for metastatic urothelial cancer (mUC).

30 Jul 2016

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors.

8 Jul 2016

Immunotherapy drugs given after chemotherapy may benefit ovarian cancer patients

Women with advanced ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy, according to a new study published in Clinical Cancer Research today.

15 Jun 2016

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Non-small cell lung cancers have a collective reputation for not responding very well to chemotherapy. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are presenting a means of evaluating an immunotherapy that fights off NSCLC by strengthening a patient's own immune system.

14 Jun 2016